Plain-English translation of NCT07600736 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help children and young adults with KCNT1-related epilepsy have fewer seizures. The study has three parts: first, all participants take the medication for 12 weeks; second, some participants randomly receive the medication while others receive a placebo (a dummy pill) for 12 weeks; and third, anyone who completes the first or second part can continue taking the medication if they wish. The main goal is to understand whether this treatment is safe and actually works to reduce seizures.
KCNT1-related epilepsy is a rare but serious genetic form of epilepsy that causes frequent seizures and is often hard to control with standard seizure medications. This trial exists because there is a need for new treatment options that might work better for children living with this condition.
You likely qualify if…
You likely don't qualify if…
If you join, you will take the new medication (or placebo in the second part) by mouth for 12 weeks, followed by a 2-week follow-up period where you'll be monitored for any side effects. You'll have visits with the study team to check how you're doing, track your seizures, and run tests to make sure the medication is safe. If the first or second part goes well, you'll have the option to continue receiving the medication in a third, longer-term phase of the study.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Actio Biosciences, Inc.
Enrollment target
~45 participants
Started
May 2026
Primary completion
January 2027
Age range
1 Month – 21 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Medical Diretor Actio Biosciences, Inc.
Actio Biosciences, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.